Back

D-cycloserine, a mixed NMDAR agonist/antagonist is Not Susceptible to Self-administration, unlike S-ketamine Using an Intravenous Self-administration Model in Naive and Ketamine-habituated Sprague-Dawley Rats

Javitt, D. C.; Javitt, J. C.

2022-08-15 neuroscience
10.1101/2022.08.12.503713 bioRxiv
Show abstract

OBJECTIVEN-methyl D-aspartate Receptor (NMDAR) antagonist antidepressants have known potential for abuse liability. The aim of this study was to evaluate the abuse liability of D-cycloserine (DCS), using a self-administration paradigm in which DCS was tested in its efficacy in substituting for ketamine in ketamine-dependent rats. METHODSA standard Intravenous self-administration study was conducted in Male adult Sprague-Dawley rats. model to study compounds abuse liability. Potential for self-administration was assessed in ketamine-habituated subjects. Subjects were trained to press a lever to obtain food, prior to connection of the lever to intravenous drug administration apparatus. DCS was provided for self-infusion by test subjects at doses of 1.5, 5.0, and 15mg/kg per lever press. RESULTSS-Ketamine was seen to substitute for ketamine and to result in self-administration at the same frequency. DCS was not seen to result in any self-administration at any of the test doses. The self-infusion behavior of DCS was the same as that of saline. CONCLUSIONC-cycloserine, an a mixed agonist/antagonist of the NMDAR glycine site, which has been shown to have antidepressant and anti-suicidal properties in clinical studies has no apparent potential for abuse liability in a standard rodent self-administration model.

Matching journals

The top 6 journals account for 50% of the predicted probability mass.

1
PLOS ONE
4510 papers in training set
Top 8%
19.2%
2
Journal of Psychopharmacology
14 papers in training set
Top 0.1%
12.7%
3
Neuropsychopharmacology
134 papers in training set
Top 0.4%
7.4%
4
Psychopharmacology
59 papers in training set
Top 0.1%
7.0%
5
Behavioural Brain Research
70 papers in training set
Top 0.2%
3.2%
6
Pharmacology Biochemistry and Behavior
17 papers in training set
Top 0.1%
3.0%
50% of probability mass above
7
Scientific Reports
3102 papers in training set
Top 49%
2.1%
8
Brain Sciences
52 papers in training set
Top 0.5%
1.9%
9
Neuropharmacology
60 papers in training set
Top 0.4%
1.8%
10
Frontiers in Psychiatry
83 papers in training set
Top 2%
1.7%
11
Frontiers in Pharmacology
100 papers in training set
Top 2%
1.5%
12
BMC Psychiatry
22 papers in training set
Top 0.4%
1.5%
13
Life Sciences
25 papers in training set
Top 0.6%
1.5%
14
Addiction Neuroscience
17 papers in training set
Top 0.3%
1.5%
15
Neuroscience Letters
28 papers in training set
Top 0.8%
1.0%
16
Journal of Affective Disorders
81 papers in training set
Top 1%
0.8%
17
Progress in Neuro-Psychopharmacology and Biological Psychiatry
36 papers in training set
Top 0.9%
0.8%
18
Schizophrenia Research
29 papers in training set
Top 0.5%
0.8%
19
Addiction Biology
47 papers in training set
Top 0.7%
0.8%
20
Translational Psychiatry
219 papers in training set
Top 4%
0.8%
21
Heliyon
146 papers in training set
Top 5%
0.8%
22
Archives of Clinical and Biomedical Research
28 papers in training set
Top 2%
0.8%
23
International Journal of Molecular Sciences
453 papers in training set
Top 15%
0.8%
24
Brain and Behavior
37 papers in training set
Top 1%
0.8%
25
ACS Chemical Neuroscience
60 papers in training set
Top 2%
0.8%
26
eneuro
389 papers in training set
Top 10%
0.7%
27
Pharmacological Research
15 papers in training set
Top 0.4%
0.7%
28
Neuroscience
88 papers in training set
Top 3%
0.7%
29
Acta Neuropsychiatrica
12 papers in training set
Top 1%
0.5%
30
Biomedicine & Pharmacotherapy
43 papers in training set
Top 1%
0.5%